Diabetes, cognitive impairment, and dementia
- 3 January 2008
- Vol. 336 (7634), 6
- https://doi.org/10.1136/bmj.39386.664016.be
Abstract
Footnotes Competing interests: All authors are grant holders for the ET2DS, a substudy of which is supported by Pfizer. MWJS has received consultancy fees, fees for speaking, and reimbursement for attending a symposium from GlaxoSmithKline (GSK), manufacturers of rosiglitazone. MWJS also sits on a GSK independent data monitoring committee. MWJS has received funds to support staff members from other companies that make drugs for diabetes—Takeda, Pfizer, and Sanofi Aventis. JFP has received research funding from Bayer Healthcare. BMF has received research funding, consultancy fees, and honorariums for lectures from Eli Lilly, Takeda, GSK, Sanofi-Aventis, and Novo Nordisk. Provenance and peer review: Not commissioned; externally peer reviewed.Keywords
This publication has 11 references indexed in Scilit:
- The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): Rationale, Design, and MethodsThe American Journal of Cardiology, 2007
- Long-Term Effect of Diabetes and Its Treatment on Cognitive FunctionNew England Journal of Medicine, 2007
- Diabetes and brain damage: more (or less) than meets the eye?Diabetologia, 2006
- Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 DiabetesDiabetes Care, 2006
- Risk of dementia in diabetes mellitus: a systematic reviewThe Lancet Neurology, 2006
- Acute Hyperglycemia Alters Mood State and Impairs Cognitive Performance in People With Type 2 DiabetesDiabetes Care, 2004
- Cognitive Ability and Brain Structure in Type 1 DiabetesDiabetes, 2003
- Retinal Microvascular Abnormalities and Cognitive Impairment in Middle-Aged PersonsStroke, 2002
- Is Type II Diabetes Associated With an Increased Risk of Cognitive Dysfunction?: A critical review of published studiesDiabetes Care, 1997
- Severe hypoglycaemia and cognitive impairment in diabetesBMJ, 1996